araag2/HINT huggingface dataset:
Clinical trial NCT00326378 (phase 3, status: completed)
Conditions: carcinoma, non-small-cell lung
ICD codes: D02.20, D02.21, D02.22
Drugs: consolidation chemotherapy with docetaxel plus cisplatin, ccrt arm without consolidation chemotherapy
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically proven non-small cell lung cancer

          -  Presence of measurable disease by RECIST

          -  Inoperable Stage IIIA or IIIB, proven by CT or MRI (except wet T4). However, N2 or N3
             should be confirmed by PET or pathology. (For T4, PET is optional)

          -  18 years of age or older

          -  ECOG Performance status 0-1

          -  No prior chemotherapy, radiation therapy to chest, immunotherapy, or biologic therapy

          -  Serum Hgb ≥ 10 gm/dL, platelet ≥ 100,000/μL, absolute neutrophil count ≥ 1,500/μL

          -  Serum creatinine ≤1.25 x UNL or creatinine clearance ≥60 mlmL/min

          -  Serum bilirubin ≤ 1.5 x UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 x UNL, alkaline
             phosphatase ≤ 5 x UNL

          -  FEV1> 0.8 L

          -  Patients must sign an informed consent

        Exclusion Criteria:

          -  Carcinoid tumor, small cell carcinoma of lung

          -  Patients with any distant metastasis

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and cured carcinoma in-situ of uterine cervix

          -  Any other morbidity or situation with contraindication for chemotherapy (e.g. active
             infection, myocardial infarction preceding 6 months, symptomatic heart disease
             including unstable angina, congestive heart failure or uncontrolled arrhythmias,
             immunosuppressive treatment)

          -  Pregnant or lactating women, women who has not taken test of pregnancy (within 14 days
             before the first administration) and pregnant women

          -  Women and men of childbearing potential who have no willing of employing adequate
             contraception
Clinical trial NCT00103662 (phase 3, status: completed)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: granulocyte colony-stimulating factor plus plerixafor, granulocyte colony-stimulating factor plus placebo
SMILES: C(N1CCCNCCNCCCNCC1)C1=CC=C(CN2CCCNCCNCCCNCC2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of multiple myeloma in first or second complete or partial remission

          -  >= 4 weeks since last cycle of chemotherapy (thalidomide, dexamethasone, and Velcade
             were not considered prior chemotherapy for the purpose of this study)

          -  Recovered from all acute toxic effects of prior chemotherapy

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

          -  White Blood Cell count (WBC) > 2.5*10^9/L

          -  Absolute polymorphonuclear leukocytes (PMN) count > 1.5*10^9/L

          -  Platelet (PLT) > 100*10^9/L

          -  Serum creatinine <=2.2 mg/dL

          -  Cardiac and pulmonary status sufficient to undergo apheresis and transplantation

          -  Negative for HIV

        Exclusion Criteria):

          -  Failed previous stem cell collection

          -  Previous stem cell transplantation

          -  Brain metastases or myelomatous meningitis

          -  Radiation to ≥ 50% of the pelvis

          -  Abnormal electrocardiogram (ECG) with rhythm disturbance (ventricular arrhythmias) or
             other conduction abnormality

          -  Received bone-seeking radionuclides (e.g. holmium)

          -  A residual acute medical condition resulting from prior chemotherapy
Clinical trial NCT00452530 (phase 3, status: completed)
Conditions: deep vein thrombosis, pulmonary embolism
ICD codes: I82.491, I82.492, I82.493, I82.499, I82.591, I82.592, I82.593, I27.82, Z86.711, I26.01, I26.09, I26.90, I26.99, I26.93
Drugs: enoxaparin, apixaban, enoxaparin-matching placebo, apixaban-matching placebo
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H], COC1=CC=C(C=C1)N1N=C(C(N)=O)C2=C1C(=O)N(CC2)C1=CC=C(C=C1)N1CCCCC1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria

          -  Patients scheduled for either elective unilateral or same-day bilateral total knee
             replacement surgery (TKR) or a revision of at least 1 component of a TKR

          -  Patients willing and able to undergo bilateral ascending contrast venography

        Key Exclusion Criteria

          -  Known or suspected hereditary or acquired bleeding or coagulation disorders in the
             participant or his or her first-degree relative

          -  Known or suspected history of heparin-induced thrombocytopenia

          -  Known coagulopathy

          -  Active bleeding or at high risk for bleeding

          -  Brain, spinal, ophthalmologic, or major surgery or trauma within the past 90 days

          -  Active hepatobiliary disease

          -  Alcohol and/or substance abuse within the past year

          -  Any condition for which, in the opinion of the investigator, surgery or administration
             of an anticoagulant was contraindicated

          -  Two consecutive blood pressure readings within 15 to 30 minutes with supine systolic
             blood pressure >180 mm Hg or supine diastolic blood pressure >105 mm Hg

          -  Clinically significant laboratory abnormalities at the enrollment visit:

               -  Hemoglobin <10 g/dL

               -  Platelet count <100,000/mm^3

               -  Creatinine clearance <30 mL/min, as estimated by the method of Cockcroft and
                  Gault

               -  Alanine aminotransferase or aspartate aminotransferase level >2*upper limit of
                  normal (ULN) or a total bilirubin ≥1.5*ULN (unless an alternative causative
                  factor such as Gilbert's syndrome was identified)
Clinical trial NCT00699283 (phase 3, status: terminated)
Conditions: epilepsy
ICD codes: G40.803, G40.804, G40.911, G40.919, G40.B11, G40.B19, G40.801
Drugs: brivaracetam, brivaracetam
SMILES: CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1, CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1
Reason stopped: 
    an interim analysis revealed the study was unlikely to attain a positive outcome for the
    efficacy analysis. no safety concerns were detected
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects from 16 to 75 years, both inclusive

          -  Well-characterized focal epilepsy or epileptic syndrome

          -  Subjects having at least 2 but not exceeding 40 partial onset seizures, whether or not
             secondarily generalized per 4 weeks during the 8-week Baseline Period

          -  Subjects on a stable dose of at least 1 but no more than 2 concomitant Antiepileptic
             Drugs (AEDs) with the second AED ≤ 50% of the minimum recommended maintenance dose

        Exclusion Criteria:

          -  Seizure type IA non-motor as only seizure type

          -  History or presence of seizures occurring too frequently or indistinctly separated to
             be reliably counted during the 6 months preceding Visit 1 or during Baseline

          -  Other serious uncontrolled disease
Clinical trial NCT00002623 (phase 3, status: completed)
Conditions: lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: carboplatin, cisplatin
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically proven primary unresectable non-small cell lung cancer
             (NSCLC) by mediastinoscopy, mediastinotomy, thoracotomy, video-assisted thoracic
             surgery, or needle biopsy

               -  Stage IIIA (N2) disease by chest CT scan

               -  Any histologic subtype allowed

          -  At least 1 unidimensionally or bidimensionally measurable target lesion on chest CT
             scan

          -  No N3 or metastatic disease by physical exam, CT scan of thorax, bone scan, and CT
             scan or ultrasound of liver and adrenals

          -  No pre-existing pleural or pericardial effusion

          -  No symptomatic CNS involvement

        PATIENT CHARACTERISTICS:

        Age:

          -  Over 18

        Performance status:

          -  WHO 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Not specified

        Hepatic:

          -  Not specified

        Renal:

          -  Not specified

        Cardiovascular:

          -  No superior vena cava syndrome

        Pulmonary:

          -  No diffuse interstitial pulmonary fibrosis

        Other:

          -  No prior melanoma, breast cancer, or hypernephroma

          -  No other primary malignancy within the past 5 years except adequately treated basal
             cell skin cancer or carcinoma in situ of the cervix

          -  No grade 2 or greater pre-existing motor or sensory neurotoxicity

          -  No active uncontrolled infection requiring IV antibiotics

          -  Must be physically and mentally fit for study therapy

          -  No psychological, familial, sociological, or geographical condition that would
             preclude study compliance

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  Not specified

        Chemotherapy:

          -  No prior chemotherapy for NSCLC

        Endocrine therapy:

          -  Not specified

        Radiotherapy:

          -  No prior radiotherapy for NSCLC

        Surgery:

          -  No prior surgery for NSCLC

        Other:

          -  No other prior therapy for NSCLC
Clinical trial NCT00101582 (phase 3, status: completed)
Conditions: mucositis, solid tumors, stomatitis, head and neck cancer, squamous cell carcinoma
ICD codes: J34.81, K92.81, K12.30, K12.39, K12.33, N76.81, K12.31, B08.61, B37.0, A69.0, K12.1, B08.4, C76.0, C47.0, C49.0, C77.0, D17.0, D21.0, D36.11, C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: placebo, palifermin, cisplatin chemotherapy
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CS(=O)(=O)CCNCC1=CC=C(O1)C1=CC2=C(C=C1)N=CN=C2NC1=CC(Cl)=C(OCC2=CC(F)=CC=C2)C=C1
Eligibility criteria:

        Key Inclusion Criteria:

          -  Histologically documented squamous cell carcinoma involving either the oral cavity,
             oropharynx, nasopharynx, hypopharynx, or larynx

          -  Newly diagnosed, locally advanced stage head and neck cancer (unresectable/unresected
             disease); American Joint Committee on Cancer [AJCC] Stage III, IVA or IVB amenable to
             radiotherapy with concurrent chemotherapy as the definitive treatment modality

          -  At least 50 Gray of radiation treatment to areas of the oral cavity/oropharynx mucosa
             that can be visualized

          -  Concurrent chemotherapy regimen of Cisplatin 100mg/m^2 on days 1, 22, and 43

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) less than or equal
             to 2

          -  Adequate hematologic, renal and hepatic function

          -  Negative pregnancy test by serum or urine

          -  Signed informed consent

        Key Exclusion Criteria:

        - Presence or history of any other primary malignancy (other than curatively treated in
        situ cervical cancer, or basal cell carcinoma of the skin without evidence of disease for
        greater than 3 years)
Clinical trial NCT00003120 (phase 3, status: completed)
Conditions: fallopian tube cancer, ovarian cancer, peritoneal cavity cancer
ICD codes: C57.00, C57.01, C57.02, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C30.0, Z12.81, D14.0, C14.8, D37.09, Z86.003, Z85.818
Drugs: paclitaxel
SMILES: [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically confirmed advanced ovarian epithelial, fallopian
        tube, or primary peritoneal cancer Must have undergone an initial exploratory laparotomy
        with tumor debulking AND Must be FIGO stage IIIA, IIIB, IIIC, or IV at the time of initial
        laparotomy Must have attained a clinically defined complete remission (CR) following
        treatment with platinum (cisplatin or carboplatin) and paclitaxel based combination
        chemotherapy regimen by achieving the following: No evidence of cancer on physical
        examination CA-125 no greater than 35 units/mL Creatinine no greater than 2.0 mg/dL OR
        Creatinine clearance greater than 60 mL/min Bilirubin no greater than 2.0 mg/dL Negative
        ascites No evidence of residual cancer on CT scan of the abdomen/pelvis or chest x-ray (or
        chest CT scan, if performed) No symptoms felt to be secondary to persistent malignancy Must
        have received a minimum of 5 and a maximum of 6 courses of chemotherapy prior to study Must
        register for study within 21 to 56 days after prior chemotherapy Not concurrently
        registered to SWOG-S9618, SWOG-S9619, SWOG-S9912, or SWOG-S0009 or front line treatment
        phase III GOG trials

        PATIENT CHARACTERISTICS: Age: Any age Performance status: SWOG 0-2 Life expectancy: Not
        specified Hematopoietic: Granulocyte count at least 1,200/mm3 Platelet count at least
        100,000/mm3 Hepatic: See Disease Characteristics Renal: See Disease Characteristics Other:
        No prior malignancy within past 5 years except adequately treated basal cell or squamous
        cell skin cancer, carcinoma in situ of the cervix, or incidental carcinoid

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent antitumor treatment No concurrent
        immunotherapy Chemotherapy: See Disease Characteristics Recovered from prior chemotherapy
        Prior cisplatin allowed if initial dose at least 50 mg/m2 Prior carboplatin allowed if
        initial dose at least 300 mg/m2 or AUC at least 4 No other concurrent chemotherapy
        Endocrine therapy: No concurrent hormonal therapy Radiotherapy: No concurrent radiotherapy
        No prior abdominal/pelvic irradiation Surgery: See Disease Characteristics No second look
        laparotomy or laparoscopy
Clinical trial NCT01009580 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/insulin aspart, biphasic insulin aspart 30
SMILES: [Na+].[Na+].[O-]P([O-])(F)=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Type 2 diabetes mellitus (diagnosed clinically) for at least 6 months

          -  Subjects on premixed human or analogue insulin or self-mixed insulin regimen,
             containing 20-40 % fast/rapid-acting component, once daily (OD) or twice daily (BID),
             with or without oral antidiabetic drugs) (OADs) (metformin, sulphonylurea (SU),
             glinides, alpha-glucosidase inhibitor, DPP-4 (dipeptidyl peptidase-4) inhibitor and
             pioglitazone), for at least 3 months before Visit 1

          -  HbA1c 7.0-10.0 % (both inclusive) by central laboratory analysis

          -  Body Mass Index (BMI) below or equal to 40.0 kg/m^2

        Exclusion Criteria:

          -  Treatment with other insulin regimens than those listed in key inclusion criterion no.
             2 within 3 months

          -  Treatment with rosiglitazone or glucagon-like peptide-1 (GLP-1) receptor agonists
             (exenatide, liraglutide) within 3 months prior to visit 1

          -  Cardiovascular disease within the last 6 months prior to visit 1, defined as: stroke;
             decompensated heart failure New York Heart Association (NYHA) class III or IV;
             myocardial infarction; unstable angina pectoris; or coronary arterial bypass graft or
             angioplasty

          -  Uncontrolled treated/untreated severe hypertension (systolic blood pressure at least
             180 millimetre (mm) mercury (Hg) and/or diastolic blood pressure at least 100 mmHg)

          -  Pregnancy, breast-feeding, the intention of becoming pregnant or not using adequate
             contraceptive measures according to local requirements

          -  Cancer and medical history of cancer (except basal cell skin cancer and squamous cell
             skin cancer
Clinical trial NCT00330317 (phase 3, status: completed)
Conditions: breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: letrozole
SMILES: N#CC1=CC=C(C=C1)C(N1C=NC=N1)C1=CC=C(C=C1)C#N
Eligibility criteria:

        Inclusion Criteria:

          1. Postmenopausal women able to comply with the protocol requirements with confirmed
             primary invasive breast cancer whose tumours are estrogen-and/or progesterone-receptor
             positive

          2. Clinical stage T2 or >T2 tumours which in the investigators' opinion would not be
             eligible for breast-conserving surgery. The nodal status will be evaluated by
             palpation and/or ultrasound.

          3. Postmenopausal status defined by one of the following:

               -  Women with an intact uterus AND

                    -  ≥ 55 years of age, OR

                    -  < 55 years of age without menses for the last 5 years, OR

                    -  < 55 years of age and have not had menses for at least the last 12 months
                       (but have had menses in the last 5 years) and have postmenopausal levels of
                       follicle-stimulating hormone.

               -  Women without an intact uterus AND

                    -  ≥ 55 years of age, OR

                    -  < 55 years of age and postmenopausal levels of follicle-stimulating hormone

               -  Both ovaries removed (prior to the diagnosis of breast cancer).

          4. Tumour measurable by clinical examination, mammography and ultrasound

          5. Adequate bone marrow function as shown by:

               -  WBC ≥ 3.5 x 10^9/L

               -  ANC ≥ 1.5 x 10^9/L

               -  Platelets ≥ LLN

               -  Hb > 10 g/dL

        Exclusion Criteria:

          1. Multifocal disease (cancer that starts in several different sites)

          2. Patients with bilateral breast tumours.

          3. Patients who are eligible for breast conserving surgery.

          4. Evidence of inflammatory breast cancer or distant metastasis.

          5. Simultaneous anti-cancer treatments such as chemotherapy, immunotherapy/biological
             response modifiers, endocrine therapy (including steroids), bisphosphonate therapy and
             radiotherapy. NOTE: Bisphosphonate therapy for osteoporosis is NOT excluded, and can
             be continued. Patients who have received hormone replacement therapy will NOT be
             excluded if it is discontinued at least 2 weeks before starting the study.

        The following additional treatments are NOT allowed during the treatment phase of the
        study:

          -  Any other anti-cancer therapy

          -  Hormone replacement therapy.

          -  Estrogen cream (including any intra-vaginal preparation).

          -  Steroids other than creams or inhalers.

          -  Megestrol acetate for the treatment of hot flushes.

          -  Radiation therapy.

        Other protocol-defined inclusion/exclusion criteria may apply.
Clinical trial NCT00151892 (phase 3, status: completed)
Conditions: ulcerative colitis
ICD codes: K51.80, K51.813, K51.814, K51.90, K51.913, K51.914, K51.811
Drugs: spd476, asacol
SMILES: NC1=CC(C(O)=O)=C(O)C=C1, NC1=CC(C(O)=O)=C(O)C=C1
Eligibility criteria:

        Inclusion Criteria:

          -  previous diagnosis of ulcerative colitis confirmed by histology that has been
             considered to be in remission for => 30 days

          -  female subjects must be post-menopausal, surgically or biologically sterile, or with a
             negative urine pregnancy test at screening and on adequate contraception

        Exclusion Criteria:

          -  proctitis

          -  previous resective colonic surgery

          -  Crohn's disease

          -  hypersensitivity to salicylates

          -  moderate/severe renal impairment
Clinical trial NCT01521962 (phase 3, status: completed)
Conditions: diabetes mellitus
ICD codes: P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9
Drugs: alogliptin, insulin
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, [Na+].[Na+].[O-]P([O-])(F)=O
Eligibility criteria:

        Inclusion Criteria:

          1. The subject is an outpatient.

          2. The subject signs and dates a written, informed consent form and any required privacy
             authorization prior to the initiation of any study procedures.

        Exclusion Criteria:

          1. The subject has any serious cardiac disease, serious cerebrovascular disorder, or any
             serious pancreatic or hematological disease.

          2. The subject is considered ineligible for the study for any other reason by the
             investigator or subinvestigator.
Clinical trial NCT00425308 (phase 3, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: everolimus + cyclosporine, everolimus + enteric-coated mycophenolate sodium (ec-mps), steroids
SMILES: CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C, [H][C@@]12C[C@@H](C)[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria:

          -  Patients who participated in and completed study CRAD001A2420

        Exclusion criteria:

          -  Premature study or study treatment discontinuation in CRAD001A2420 study.

          -  Acute rejection within the 3 months prior to inclusion

        Other protocol-defined inclusion/exclusion criteria may apply